SuperScript IV Reverse Transcriptase, 4 x 10,000 Units and 3 more items

Life Technologies Corporation was awarded contract A207_PO-0445950-V3 by the University of Virginia on July 11, 2026, with a cumulative value of $7,978.41. The contract encompasses the supply of molecular biology reagents and enzymes essential for nucleic acid analysis and reverse transcription applications. The line items include SuperScript IV Reverse Transcriptase (5,404 units), Random Hexamers at 50 micromolar concentration (812 units), RNaseOUT Recombinant Ribonuclease Inhibitor (1,384 units), and dNTP Mix at 10 millimolar concentration in 1 milliliter volumes (377 units).

The procurement represents a purchase order arrangement for laboratory consumables to support the University of Virginia's research and analytical operations. All materials are designated for delivery to the buyer, with unit pricing established at $1.00 per item across all line items. While specific performance periods and annual value parameters are not delineated in the available documentation, the contract award reflects a procurement of standard molecular biology reagent kits commonly utilized in academic research environments for gene expression studies, complementary DNA synthesis, and related molecular diagnostic applications.